Using a Transection Paradigm to Enhance the Repair Mechanisms of an Investigational Human Cell Therapy

• Published in: Cell transplantation Vol. 31; p. 9636897221123515
• Main Authors: Chau, Monica J., Quintero, Jorge E., Monje, Paula V., Voss, Stephen Randal, Welleford, Andrew S., Gerhardt, Greg A., van Horne, Craig G.
• Format: Journal Article
• Language: English
• Published: Los Angeles, CA SAGE Publications 2022; Sage Publications Ltd; SAGE Publishing
• Subjects: Apoptosis; Brain-Derived Neurotrophic Factor; Cell therapy; Cell- and Tissue-Based Therapy; Glial cell line-derived neurotrophic factor; Glial Cell Line-Derived Neurotrophic Factor - genetics; Humans; Immunoassay; Movement disorders; Nerve Growth Factor; Nervous system; Neurodegeneration; Neurodegenerative diseases; Neuroprotection; Original; Parkinson Disease - therapy; Parkinson's disease; Peripheral nerves; Proto-Oncogene Proteins c-sis; RNA; Substantia nigra; Sural nerve; Transplantation; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A; tissue-based therapy; single nuclei RNA sequencing; peripheral nerve; cell therapy; neuroprotection

One promising strategy in cell therapies for Parkinson’s disease (PD) is to harness a patient’s own cells to provide neuroprotection in areas of the brain affected by neurodegeneration. No treatment exists to replace cells in the brain. Thus, our goal has been to support sick neurons and slow neurod...